| |
DM |
PM |
OS |
| |
74 (100%) |
20 (100%) |
24 (100%) |
| Age (mean ± SD; Range 15-70), years |
35.01±15.43 |
41.45±12.1 |
41.88±15.54 |
Female
Male |
50 (68)
24 (32) |
15 (75)
5 (25) |
18 (75%)
6 (25%) |
| Follow-up (mean ± SD), months |
61.64 ±56.1 |
76.4±63.67 |
82.42±73.93 |
| Diagnostic Criteria |
|
|
|
| Proximal weakness |
73 (99%) |
20 (100%) |
24 (100%) |
| High CK Ul/L (>263) |
61/73 (84%) |
19/20 (95%) |
18/23 (78%) |
| Myopathic changes on EMG |
49/50 (98%) |
16/16 (100%) |
13/15 (87%) |
Muscle biopsy
Normal
Atrophy
Inespecific regeneration
Compatible |
3/52 (6%)
2/52 (4%)
4/52 (8%)
43/52 (83%) |
3/16 (19%)
0
1/16 (6%)
12/16 (75%) |
0
1/20 (5%)
3/20 (15%)
16/20 (80%) |
| Cutaneous findings |
74 (100%) |
0 |
12 (50%) |
Bohan and Peter
Definite
Probable
Possible |
57 (77%)
16 (22%)
1 (1%) |
11 (55%)
6 (30%)
3 (15%) |
14 (58%)
8 (33%)
2 (8%) |
| Other clinical features: |
|
|
|
Systemic symptoms
Weight loss only >5%
Fever only
Both |
36 (49%)
23 (31%)
4 (5%)
9 (12%) |
15 (75%)
11 (55%)
0
4 (20%) |
13 (54%)
7 (29%)
1 (4%)
5 (21%) |
| Raynaud´s phenomenon |
14 (19%) |
1 (5%) |
8 (33%) |
| Other laboratory data: |
|
|
|
| High LDH (>164 UI/L) |
62/70 (89%) |
19/19 (100%) |
20/24 (83%) |
| Low Hemoglobin (<14 g/dL) |
26 (35%) |
6 (30%) |
12 (50%) |
| Low Albumin (< 3.5 g/dL) |
31/70 (44%) |
5/18 (28%) |
14/24 (58%) |
| Elevated ESR |
26/69 (38%) |
4/18 (22%) |
12/21 (57%) |
| Positive ANA |
33/62 (53%) |
4/17 (24%) |
17/21 (81%) |
| CK= Creatine Kinase; EMG= Electromyography; LDH= Lactate Deshydrogenase; ESR= Erythrocyte Sedimentation Rate; ANA= Antinuclear Antibodies. |
